BiotechTube
Indi Molecular

Indi Molecular

San Diego, United States· Est.
indimolecular.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.8M

Overview

Indi Molecular is a private, preclinical-stage biotech leveraging its proprietary Protein Catalyzed Capture (PCC) platform to create synthetic peptide therapeutics with antibody-like binding properties. Founded in 2012 as a spinout from Integrated Diagnostics, the company has raised a $1.5M seed round and an $11.5M Series A to advance its platform and two lead oncology programs. Its approach aims to combine the high specificity of biologics with the favorable pharmacokinetics and manufacturability of small molecules.

Oncology

Technology Platform

Protein Catalyzed Capture (PCC) Agent platform: a synthetic chemistry platform using click chemistry to generate low molecular weight, D-amino acid cyclic peptides with antibody-like, high-affinity binding to specific protein epitopes.

Funding History

1
Total raised:$1.8M
Seed$1.8M

Opportunities

The successful development of a KRAS G12D inhibitor addresses a massive unmet need in pancreatic and other solid tumors, representing a blockbuster opportunity.
The PCC platform's ability to rapidly generate drug-like peptides against challenging targets could enable a pipeline of novel therapeutics and attract lucrative partnership deals.

Risk Factors

High technical risk as the novel PCC platform is unproven in humans.
Financial risk is significant given the preclinical stage and time since last funding round.
Intense competition in both target areas from large pharma and biotechs using multiple modalities creates a high bar for success.

Competitive Landscape

Indi Molecular competes in the targeted oncology space against large pharmaceutical companies and biotechs developing monoclonal antibodies, antibody-drug conjugates (ADCs), and small molecule inhibitors. For KRAS G12D, it faces direct competition from companies like Mirati, Revolution Medicines, and others advancing small molecules and heterobifunctional degraders. In FRα-targeted ovarian cancer, it competes with ImmunoGen and other ADC developers.

More companies in Diagnostics & Precision Medicine →More companies in United States →